| Diabetes Mellitus, Non-Insulin-Dependent
Humalog 75/25 vs Victoza
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Humalog vs Victoza with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVictoza has a higher rate of injection site reactions vs Humalog based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Victoza but not Humalog, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Humalog
Victoza
At A Glance
SC injection
Twice daily
Insulin analog
SC injection
Daily
GLP-1 receptor agonist
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
- Cardiovascular Diseases
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Inject SC within 15 minutes before a meal into abdominal wall, thigh, upper arm, or buttocks; typically dosed twice daily; individualize dose based on metabolic needs and blood glucose monitoring results.
Diabetes Mellitus, Non-Insulin-Dependent, Cardiovascular Diseases (Adults) Start at 0.6 mg SC once daily for one week, then increase to 1.2 mg once daily; if additional glycemic control is required, increase to 1.8 mg once daily (maximum) after at least one week at 1.2 mg.
Diabetes Mellitus, Non-Insulin-Dependent (Pediatric >= 10 years) Start at 0.6 mg SC once daily; increase in 0.6 mg increments after at least one week on the current dose; maximum recommended dose is 1.8 mg once daily.
Contraindications
- During episodes of hypoglycemia
- Previous hypersensitivity reactions to HUMALOG Mix75/25 or any of its excipients
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Serious hypersensitivity reaction to liraglutide or any excipient in VICTOZA
Adverse Reactions
Most common Hypoglycemia
Serious Severe anaphylaxis, hypokalemia
Postmarketing Lipodystrophy, localized cutaneous amyloidosis, injection site reactions, peripheral edema, weight gain, anti-insulin antibody formation
Most common (>=5%) Nausea, diarrhea, headache, nasopharyngitis, vomiting, decreased appetite, dyspepsia, upper respiratory tract infection, constipation, back pain
Serious Risk of thyroid C-cell tumors, acute pancreatitis, hypoglycemia, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, acute gallbladder disease, pulmonary aspiration during general anesthesia or deep sedation
Postmarketing Acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation, dehydration, elevations of liver enzymes, hyperbilirubinemia, cholestasis, cholecystitis, cholelithiasis, hepatitis, angioedema, anaphylactic reactions, pruritus, medullary thyroid carcinoma, dysgeusia, dizziness, dysesthesia, pulmonary aspiration, acute renal failure, increased serum creatinine, cutaneous amyloidosis, alopecia
Pharmacology
Insulin analog; regulates glucose metabolism by stimulating peripheral glucose uptake by skeletal muscle and fat and inhibiting hepatic glucose production, while also inhibiting lipolysis and proteolysis and enhancing protein synthesis.
GLP-1 receptor agonist; liraglutide is an acylated human GLP-1 analog (97% amino acid sequence homology to endogenous human GLP-1(7-37)) that stimulates glucose-dependent insulin secretion, suppresses glucagon secretion, and delays gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Humalog
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (9/12)
Victoza
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Humalog
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Victoza
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (5/8)
Humana
Humalog
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (0/3)
Victoza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Humalog.
No savings programs available for Victoza.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HumalogView full Humalog profile
VictozaView full Victoza profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.